Focus on Asthma Care

Back to articles

Lebrikizumab provides insights into interleukin-13 role in asthma

September 13, 2011
  • Advising on this article:
  • Devra K. Dang

KEY POINT

Treatment with the experimental drug lebrikizumab, a humanized monoclonal antibody to interleukin-13, increased lung function in adults with asthma. Drug effects in the Phase II trial were greater in individuals with high levels of the protein periostin, which is secreted by bronchial epithelial cells in response to interleukin-13.

SOURCES

Corren J et al. Lebrikizumab treatment in adults with asthma. N Engl J Med. 2011 Aug 3. Epub ahead of print.

Recent Articles

2215 Constitution Avenue NW, Washington, DC 20037 Telephone 202-628-4410 Fax 202-783-2351

© 2011 American Pharmacists Association All Rights Reserved.

About the American
Pharmacists Association

The American Pharmacists Association (APhA) is the organization whose members are recognized in society as essential in all patient care settings for optimal medication use that improves health, wellness and quality of life. Through information, education and advocacy, APhA empowers its members to improve medication use and advance patient care.

More info

About APhA DrugInfoLine

APhA DrugInfoLine (ISSN 2162-3015) is a weekly publication of, and is owned and copyrighted by the American Pharmacists Association, the national professional society of pharmacists. Materials in APhA DrugInfoLine do not neccessarily represent the policy, recommendations, or endorsement of APhA. The publisher, authors, editors, reviewers, and contributors have taken care to ensure that the information contained in APhA DrugInfoLine is accurate and current; however, they shall have no ability to any person or entity with regard to claims, losses, or damage caused or alleged to be caused, directly or indirectly by use of any information contained in the publication. All decisions about drug therapy must be based on independent judgement of the clinician.